Medication for preventing and improving memory loss

Abstract

We provide a drug that uses herbal ingredients to help prevent and treat memory loss. [Solution] The formula contains at least red ginseng and Polygala tenuifolia, and in addition, Angelica sinensis, Ligusticum chuanxiong, Peony root, Rehmannia glutinosa, Glycyrrhiza uralensis, Poria cocos, Atractylodes macrocephala, Viper rhizome, Dioscorea japonica, Schisandra chinensis, and ox bile as active ingredients.

Description

Technical Field

[0001] The present invention relates to a drug for preventing and improving memory loss.

Background Art

[0002] On the background of rapid aging, it is estimated that by 2025, one in five people aged 65 or older (about 7 million people) will suffer from dementia, which may become a social problem. Dementia is broadly classified into dementia due to organic brain disorders, dementia associated with organ diseases other than the brain, and dementia caused by physical diseases due to stress. Among them, dementia due to organic brain disorders is considered to account for the majority of the causes of dementia. In addition, organic brain disorders mainly consist of Alzheimer's dementia and vascular dementia due to different causes. It is known that 70% of the causes are Alzheimer's dementia and 20% are vascular dementia.

[0003] Alzheimer's dementia is a disease mainly characterized by cognitive decline and personality changes. Although, as mentioned above, it accounts for a large proportion of senile dementia, there are still many unclear points about its pathogenesis. Therefore, for Alzheimer's dementia, there are Western medical anti-dementia drugs such as donepezil hydrochloride (see Patent Document 1), which can temporarily improve cognitive function. In recent years, Western medical anti-dementia drugs such as lecanemab and donanemab have been approved (see Non-Patent Document 1). However, all of these Western medical anti-dementia drugs cannot treat the pathological condition of dementia or ultimately prevent the deterioration of dementia. Moreover, the use of these Western medical anti-dementia drugs often causes side effects such as loss of appetite, nausea, vomiting, diarrhea, rash, and itching (see Non-Patent Document 2).

[0004] Furthermore, vascular dementia is a disease that develops as a sequela of cerebral infarction or cerebral hemorrhage, and exhibits a variety of symptoms including disorientation regarding place, time, and people, memory impairment, decreased motivation, emotional disturbances, depressive symptoms, and behavioral abnormalities. While psychotropic drugs (mainly anxiolytics and antidepressants) and drugs that improve cerebral circulation and metabolism have been used to treat vascular dementia, satisfactory effects have not always been achieved. Moreover, the use of these drugs often resulted in side effects such as drowsiness, fatigue, and nausea.

[0005] Therefore, the applicant of the present invention has already proposed and obtained a patent for an anti-dementia herbal medicine preparation containing, in addition to Angelica sinensis, Ligusticum chuanxiong, Peony root, Rehmannia glutinosa, Ginseng, and Licorice, Poria cocos, Atractylodes macrocephala, Cinnamon bark, Astragalus membranaceus, Viper nasi, Dioscorea japonica, Garlic, and Ox bile as active ingredients (see Patent Document 2). In other words, this anti-dementia herbal medicine preparation has the advantage of having fewer side effects compared to Western medicines, because it is made from herbal ingredients.

[0006] However, since a complete cure is difficult with either Western or traditional Chinese medicine, early detection and treatment of dementia are considered crucial. In other words, effective countermeasures would primarily involve preventative measures to avoid the onset of mild cognitive impairment (MCI), a precursor to dementia, and memory loss. [Prior art documents] [Patent Documents]

[0007] [Patent Document 1] Patent No. 2578475 [Patent Document 2] Patent No. 5634431 [Non-patent literature]

[0008] [Non-Patent Document 1] Ministry of Health, Labour and Welfare: Regarding new treatments for Alzheimer's disease (Accessed October 30, 2025) <URL: https: / / www.mhlw.go.jp / stf / seisakunitsuite / bunya / 0000089508_00007.html> [Non-Patent Document 2] "JAPIC Medical Drug Compendium 2012," Japan Pharmaceutical Information Center, September 15, 2011, pp. 1711-1714. [Overview of the project] [Problems that the invention aims to solve]

[0009] On the other hand, currently, the only over-the-counter herbal medicine whose efficacy against memory loss is recognized by the government is the single-ingredient preparation of Polygala tenuifolia (Onji). However, there is little test data demonstrating the effectiveness of Polygala tenuifolia. Furthermore, the inventor's research has revealed that Polygala tenuifolia alone does not provide long-term improvement in memory impairment.

[0010] Therefore, the inventor diligently investigated whether it would be possible to prevent or treat memory loss using other herbal medicines, and as a result, completed the present invention.

[0011] In view of the above circumstances, the present invention aims to provide a drug for preventing and improving memory loss that uses herbal ingredients and is useful for preventing and treating memory loss. [Means for solving the problem]

[0012] To achieve the above objective, the memory loss prevention and improvement drug according to the present invention (hereinafter referred to as "the memory loss prevention and improvement drug of the present invention") contains red ginseng and Polygala tenuifolia. Angelica sinensis, Ligusticum chuanxiong, Peony root, Rehmannia glutinosa, Glycyrrhiza uralensis, Poria cocos, Atractylodes macrocephala, Viper rhizome, Dioscorea japonica, Schisandra chinensis, and Ox bile It is characterized by containing as an active ingredient. 。

[0013] The present invention provides a drug for preventing and improving memory loss. While not particularly limited, in terms of crude drug equivalent, Angelica sinensis 10-1000 parts by weight, Ligusticum chuanxiong 10-2500 parts by weight, Paeonia lactiflora 10-2500 parts by weight, Rehmannia glutinosa 10-2000 parts by weight, Red ginseng 1400-10000 parts by weight, Licorice 40-1000 Preferably, it is configured to contain, as active ingredients, 10 to 30,000 parts by weight of red ginseng, 10 to 500 parts by weight of Poria cocos, 10 to 500 parts by weight of Atractylodes macrocephala, 150 to 3,000 parts by weight of Agkistrodon blomhoffii, 60 to 1,000 parts by weight of Dioscorea opposita, 150 to 1,500 parts by weight of Schisandra chinensis, 50 to 500 parts by weight of ox bile, and 250 to 500 parts by weight of Polygala tenuifolia.

[0014] Specifically, each of the above active ingredients is as follows. That is, red ginseng is the root or rootlets of Panax ginseng C.A.Meyer of the genus Panax in the family Araliaceae, steamed and dried with the rootlets attached. Polygala tenuifolia is the root or root bark of Polygala tenuifolia Willdenow of the genus Polygala in the family Polygalaceae.

[0015] Angelica acutiloba is the root of the perennial herb Angelica acutiloba Kitagawa or Angelica acutiloba Kitagawa var. sugiyamae Hikino of the genus Angelica in the family Umbelliferae. Cnidium officinale is the rhizome of the perennial herb Cnidium officinale Makino of the genus Cnidium in the family Umbelliferae.

[0016] Paeonia lactiflora is the root of the perennial herb Paeonia lactiflora Pallas of the genus Paeonia in the family Paeoniaceae. Rehmannia glutinosa is the root of the plant Rehmannia glutinosa Liboschitz var. purpurea Makino or Rehmannia glutinosa Liboschitz of the genus Rehmannia in the family Scrophulariaceae.

[0017] Licorice (Glycyrrhiza uralensis Fischer or Glycyrrhiza glabra Linne (Leguminosae)) is the root and stolon of the perennial herb of the legume family Glycyrrhiza, sometimes excluding the periderm. Poria cocos (Wolfiporia cocos Ryvarden et Gilbertson (Poria cocos Wolf)(Polyporaceae)) is the sclerotium of the mushroom of the genus Wolfiporia of the family Polyporaceae.

[0018] Atractylodes rhizome (Atractylodes japonica Koidzumi ex Kitamura or Atractylodes macrocephala Koidzumi (Atractylodes ovata De Candolle)(Compositae)) is the rhizome of the perennial herb of the genus Atractylodes of the family Compositae. Agkistrodon acutus (Gloydius blomhoffii H.Boie, Gloydius brevicaudus Stejneger) or other animals of the same genus (Viperidae) are classified in the family Crotalidae, genus Gloydius. Or it is the skin and internal organs of Ptyas dhumnades Cantor or other animals of the same genus (Colubridae) classified in the family Colubridae, genus Ptyas.

[0019] Chinese yam (Dioscorea japonica Thunberg or Dioscorea batatas Decaisne (Dioscoreaceae)) is the rhizome excluding the periderm. Schisandra chinensis (Schisandra chinensis Baillon) is the fruit of the genus Schisandra of the family Schisandraceae.

[0020] Ox bile is the dried bile of cattle (Bos taurus L.), a species of the Bovidae family.

[0021] These active ingredients can be used in their raw, unprocessed form, but it is preferable to use them as extracts obtained from the raw materials or as pulverized raw materials. Extraction and pulverization can be carried out using any known method used in the manufacture of pharmaceuticals or food products, without any particular limitations.

[0022] For example, extraction can be performed by extracting each raw material with 5 to 30 times its weight in hot water, preferably 10 to 20 times its weight, and then concentrating and drying the extract. Known methods such as vacuum evaporation, spray drying, and freeze-drying can be used for concentration and drying. Known methods such as impact mills and jet mills can be used for grinding.

[0023] The memory loss prevention and improvement drug of the present invention may be used as is after mixing the above active ingredients, or the active ingredients may be mixed with pharmaceutically acceptable additives. Examples of the above-mentioned additives include excipients, binders, disintegrants, surfactants, lubricants, flow enhancers, suspending agents, emulsifiers, sweeteners, and ethanol.

[0024] Furthermore, the memory loss prevention and improvement drug of the present invention may be mixed with the above-mentioned additives and processed into solid formulations such as granules, tablets, capsules, or pills by known methods, or it may be processed into liquid formulations such as suspensions, emulsions, syrups, or elixirs.

[0025] Furthermore, the excipients, binders, disintegrants, surfactants, lubricants, flow enhancers, suspending agents, and emulsifiers mentioned above can be used without particular limitation as long as they are known.

[0026] The above-mentioned excipients are not particularly limited, but examples include starch, lactose, sucrose, mannitol, carboxymethylcellulose, light anhydrous silicic acid, corn starch, inorganic salts, and the like. The above-mentioned binders are not particularly limited, but examples include starch, dextrin, acacia powder, gelatin, hydroxypropyl starch, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, crystalline cellulose, ethylcellulose, polyvinylpyrrolidone, macrogol, and the like.

[0027] The above-mentioned disintegrants are not particularly limited, but examples include starch, hydroxypropyl starch, sodium carboxymethylcellulose, calcium carboxymethylcellulose, carboxymethylcellulose, and low-substituted hydroxypropylcellulose. The surfactants mentioned above are not particularly limited, but examples include sodium lauryl sulfate, soy lecithin, sucrose fatty acid ester, and polysorbate 80.

[0028] The above-mentioned lubricants are not particularly limited, but examples include talc, waxes, hydrogenated vegetable oils, sucrose fatty acid esters, magnesium stearate, calcium stearate, aluminum stearate, polyethylene glycol, and the like. The above-mentioned fluidity enhancers are not particularly limited, but examples include light anhydrous silicic acid, dried aluminum hydroxide gel, synthetic aluminum silicate, magnesium silicate, and the like.

[0029] The above-mentioned suspending agent is not particularly limited, but examples include soybean oil and medium-chain triglyceride. The emulsifiers mentioned above are not particularly limited, but examples include fatty acid monoglycerides and lecithin.

[0030] The memory loss prevention and improvement drug of the present invention varies depending on the patient's age, weight, and the severity of the disease, and is not particularly limited, but it is generally preferable for adults to administer 1 to 10 g, preferably 1.5 to 3.0 g, of the active ingredient in several divided doses per day (about 3 times). It can be used together with health foods and general food products. [Effects of the Invention]

[0031] The memory-preventing and improving agent of the present invention, as described above, is made from the herbal medicines red ginseng and Polygala tenuifolia. Angelica sinensis, Ligusticum chuanxiong, Peony root, Rehmannia glutinosa, Glycyrrhiza uralensis, Poria cocos, Atractylodes macrocephala, Viper rhizome, Dioscorea japonica, Schisandra chinensis, and Ox bile Because it contains this as an active ingredient, it is highly effective in preventing and improving memory loss, and is also safe with few side effects. [Brief explanation of the drawing]

[0032] [Figure 1] This is a photograph of the step-through type passive avoidance reaction device used in the passive avoidance test. [Figure 2] This graph shows a comparison of the results of retention trial tests. [Figure 3] This is a schematic diagram illustrating the novel object recognition test. [Figure 4] This graph shows a comparison of the results of the novel object recognition test. [Figure 5] This graph compares the results of the RBANS neuropsychological test for participant A before and after taking CareAge. [Figure 6] This radar chart compares the results of the RBANS neuropsychological test for trial participant A before and after taking CareAge. [Figure 7] This graph compares the results of the RBANS neuropsychological test for participant B before and after taking CareAge. [Figure 8] This radar chart compares the results of the RBANS neuropsychological test for participant B before and after taking CareAge. [Figure 9] This graph compares the results of the RBANS neuropsychological test for participant C before and after taking CareAge. [Figure 10] This radar chart compares the results of the RBANS neuropsychological test for participant C before and after taking CareAge. [Figure 11] This graph compares the results of the RBANS neuropsychological test for participant D before and after taking CareAge. [Figure 12]This radar chart compares the results of the RBANS neuropsychological test for participant D before and after taking CareAge. [Figure 13] This graph compares the results of the RBANS neuropsychological test for participant E before and after taking CareAge. [Figure 14] This radar chart compares the results of the RBANS neuropsychological test for trial participant E before and after taking CareAge. [Modes for carrying out the invention]

[0033] The present invention will be described in detail below.

[0034] Administration solution 1 consisting of red ginseng extract (manufactured by Zaiseido Pharmaceutical Co., Ltd.), administration solution 2 consisting of mixed herbal extract (manufactured by Zaiseido Pharmaceutical Co., Ltd.), administration solution 3 consisting of Polygala extract (manufactured by Zaiseido Pharmaceutical Co., Ltd.), and administration solution 4 consisting of a tonic (product name CareAge, manufactured by Zaiseido Pharmaceutical Co., Ltd., hereinafter referred to as "CareAge") were prepared as follows.

[0035] (Preparation of administration solution 1) The required amount of red ginseng extract, which was the test substance, was weighed, and methylcellulose diluted with sterile water for injection (0.5 w / v% MC) was added in small amounts as a medium to suspend and prepare the solution to the predetermined concentration, resulting in a dosage of 590 mg / kg.

[0036] (Preparation of administration solution 2) The required amount of mixed herbal extract, which is the test substance, was weighed, suspended and prepared to the predetermined concentration using the same medium as described above, so that the dosage would be 1000 mg / kg. The mixed herbal extract used contained 150 mg of Angelica sinensis extract, 100 mg of Ligusticum chuanxiong extract, 100 mg of Paeonia lactiflora extract, 135 mg of Rehmannia glutinosa extract, and 700 mg of red ginseng extract.

[0037] (Preparation of administration solution 3) The required amount of Polygala extract was weighed out as the test substance, suspended and prepared to the specified concentration using the same medium as described above, and administered at a dose of 1000 mg / kg.

[0038] (Preparation of administration solution 4) The required amount of CareAge as the test substance was weighed, suspended and prepared to the specified concentration using the same medium as described above, and administered at a dose of 1000 mg / kg. CareAge used contained the following ingredients: 150 mg of Angelica sinensis extract, 100 mg of Ligusticum chuanxiong extract, 100 mg of Paeonia lactiflora extract, 135 mg of Rehmannia glutinosa extract, 700 mg of Red Ginseng extract, 150 mg of Licorice powder, 150 mg of Poria cocos powder, 100 mg of Atractylodes macrocephala powder, 360 mg of Viper's Root powder, 310 mg of Dioscorea japonica powder, 100 mg of Schisandra chinensis extract, 50 mg of Ox bile extract, and 72 mg of Polygala tenuifolia extract.

[0039] (Cultivation of the first sample mouse) The administration solution 1 prepared as described above was forcibly administered orally once a day at a rate of 10 mL per kg of body weight per mouse for 8 weeks to SAMP8 mice, which are mice exhibiting rapid aging and memory impairment, starting at 24 weeks of age, using a disposable polypropylene syringe (Terumo Corporation) fitted with a disposable oral tube for mice (Fuchigami Kikai Co., Ltd.), to obtain the first sample mouse.

[0040] (Cultivation of the second sample mouse) A second sample mouse was obtained in the same manner as the first sample mouse described above, except that administration solution 2 was administered instead of administration solution 1.

[0041] (Cultivation of the third sample mouse) A third mouse sample was obtained in the same manner as the first mouse sample described above, except that administration solution 3 was administered instead of administration solution 1.

[0042] (Cultivation of the fourth mouse sample) A fourth mouse sample was obtained in the same manner as the first mouse sample described above, except that administration solution 4 was administered instead of administration solution 1.

[0043] (Passive avoidance test) A step-through passive avoidance reaction apparatus was prepared, as shown in Figure 1, which consisted of a bright room (W:100 × D:100 × H:300 mm) separated by a central guillotine door and a dark room (W:240 × D:245 × H:300 mm) that applied electrical stimulation from a grid on the floor. A normal control mouse (SAMR1 mouse) that did not show memory impairment, a media control mouse (SAMP8 mouse administered only with a 0.5 w / v% MC medium), and each sample mouse (Sample 1 to 4 mouse) administered with each test substance (administration solution 1 to 4) were first placed in the bright room, and after 10 seconds the central guillotine door was opened and the time it took for the mouse to enter the dark room was measured. The memory process consists of three steps: acquisition, retention, and retrieval. Cognitive impairment is thought to occur when any of these steps are impaired. In the passive avoidance test, the following tests were conducted using acquisition trials to assess memory acquisition and retention trials to assess memory retention. The passive avoidance test is known as a test system for evaluating long-term memory.

[0044] (1) Trial examination for acquisition The SAMR1 mouse group (also called the normal control group), consisting of 10 normal control SAMR1 mice; the SAMP8 mouse group (also called the media control group), consisting of 10 SAMP8 (dementia-developing) mice; the first sample mouse group (also called the red ginseng extract group), consisting of 10 first sample mice; the second sample mouse group (also called the mixed herbal extract group), consisting of 10 second sample mice; the third sample mouse group (also called the Polygala extract group), consisting of 10 third sample mice; and the fourth sample mouse group (also called the care-age group), consisting of 10 fourth sample mice, were individually placed in brightly lit rooms separated by a central guillotine door. After 10 seconds, the guillotine door was quietly opened, and as the mice entered the dark room, the guillotine door was closed, and electrical stimulation (0.1 mA, 2 sec, scrambled method) was applied. The presence or absence of vocalizations by the animals during the electrical stimulation was checked. The time it took for the mouse to enter the darkroom (reaction latency) was limited to a maximum of 300 seconds. For the behavioral test, the test was conducted one hour after the final administration of the medium and sample solution.

[0045] (2) Holding trial test SAMR1 mice (normal control), SAMP8 mice (medium control), and four sample mice (samples 1, 2, 3, and 4) were individually placed in a brightly lit room with the guillotine door open one day after the acquisition trial described above. The number of seconds it took for each mouse to enter the dark room was then measured. The test was terminated after 300 seconds in the brightly lit room.

[0046] The results of the acquisition and retention trials are shown in Tables 1 to 6, and the retention trial results are shown in comparison in Figure 2.

[0047] [Table 1]

[0048] [Table 2]

[0049] [Table 3]

[0050] [Table 4]

[0051] [Table 5]

[0052] [Table 6]

[0053] As shown in Tables 1 to 6 above, the response latency for the acquisition trials was 12.79 ± 1.92 seconds for the normal control group, 9.53 ± 0.94 seconds for the media control group, 11.52 ± 1.44 seconds for the red ginseng extract group, 11.47 ± 1.59 seconds for the mixed herbal extract group, 11.97 ± 1.89 seconds for the Polygala extract group, and 9.88 ± 1.01 seconds for the care age group. In other words, the results above indicate that no significant differences were observed between the groups in the acquisition trials, suggesting that in all groups, the mice instinctively moved to the darkroom and acquired the memory.

[0054] The response latency for the retention test to check memory retention was 290.29 ± 9.71 seconds for the normal control group, 60.79 ± 13.92 seconds for the media control group, 100.83 ± 32.18 seconds for the red ginseng extract group, 48.80 ± 12.18 seconds for the mixed herbal extract group, 89.93 ± 20.30 seconds for the Polygala extract group, and 157.43 ± 34.35 seconds for the care age group. As shown in Figure 2, the red ginseng extract group and the Polygala extract group showed a tendency toward improvement in memory impairment compared to the media control group, although there was no significant difference. The mixed herbal group, which contained red ginseng extract but not Polygala extract, showed a slight downward trend compared to the media control group. However, the care age group, which contained both red ginseng extract and Polygala extract, showed a significant improvement in memory impairment compared to the media control group. Specifically, the response latency in the retention trial in the passive avoidance test was significantly shorter in the media control group compared to the normal control group, and significantly longer in the CareAge group compared to the media control group. Therefore, it was confirmed that long-term memory in SAMP8 is impaired, and it was suggested that CareAge improves this long-term memory impairment. Thus, it is thought that combining red ginseng extract and Polygala extract, as in CareAge, is more effective in preventing and improving forgetfulness caused by long-term memory impairment than using Polygala extract alone.

[0055] (Novel Object Recognition Test) The normal control mice (n=10), media control mice (n=10), and mice from sample 1 to sample 4 (n=10) described above were tested in a novel object recognition test, consisting of acquisition trials to acquire memory and retrieval trials to evaluate memory retrieval, as described below. The novel object recognition test is known as a test system for evaluating short-term memory. (1) Trial examination for acquisition As shown in Figure 3, each mouse was placed individually in a cage containing objects (A and B), and the behavior of each mouse was videotaped for 10 minutes. The behavioral tests were conducted one hour after the final administration of the medium and sample solution. (2) Regeneration trial test This was conducted two hours after the acquisition trial. Only one object was replaced with a new object (C), and each mouse was placed back into its cage individually, and its behavior was videotaped for 5 minutes. Then, the contact time and number of contacts with each object for each mouse in the acquisition trial and the retrieval trial were measured at a later date using a stopwatch and counter. Subsequently, the percentage of contact time and the percentage of contacts with the novel object in the retrieval trial were calculated, and the results are shown in Tables 7 to 12, along with a comparison of the results of the retrieval trial in Figure 4.

[0056] [Table 7]

[0057] [Table 8]

[0058] [Table 9]

[0059] [Table 10]

[0060] [Table 11]

[0061] [Table 12]

[0062] As shown in Tables 7 to 12 and Figure 4, the percentage of contact time with novel objects was 56.68 ± 4.25% for the normal control group, 41.42 ± 2.92% for the media control group, 54.95 ± 2.42% for the red ginseng extract group, 56.26 ± 3.45% for the mixed herbal extract group, 67.44 ± 2.75% for the Polygala extract group, and 54.65 ± 1.99% for the care age group. All of the red ginseng extract group, mixed herbal extract group, Polygala extract group, and care age group showed significant improvement in memory impairment compared to the media control group. Specifically, the contact time with novel objects in the recall trials was significantly lower in the media control group compared to the normal control group, while the red ginseng extract group, mixed herbal extract group, Polygala extract group, and CareAge group showed significantly higher values ​​compared to their respective media control groups. Therefore, it was confirmed that SAMP8's short-term memory was impaired, and it was suggested that CareAge improves this short-term memory impairment. Accordingly, red ginseng extract, mixed herbal extract containing red ginseng extract, and CareAge containing Polygala extract appear to have preventive and ameliorative effects on forgetfulness caused by short-term memory impairment.

[0063] In other words, the results of the passive avoidance test and the novel object recognition test suggested that CareAge may have the potential to improve short-term and long-term memory impairments.

[0064] (Clinical trials of CareAge) (1) For a woman in her 40s with mild cognitive impairment (MCI), the RBANS neuropsychological test was administered before taking CareAge and 3 months and 2 days after taking it, and the results are shown in comparison in Figures 5 and 6. (2) For a woman in her 40s with mild cognitive impairment (B), the RBANS neuropsychological test was administered before taking CareAge and 4 months and 5 days after taking it, and the results are shown in comparison in Figures 7 and 8. (3) For a woman in her 50s with mild cognitive impairment (C), the RBANS neuropsychological test was administered before taking CareAge and 16 months and 15 days after taking it, and the results are shown in Figure 9 and Figure 10 for comparison. (4) For a mildly cognitively impaired person D (a man in his 70s), the RBANS neuropsychological test was administered before taking CareAge and 3 months and 13 days after taking it, and the results are shown in comparison in Figures 11 and 12. (5) For Alzheimer's disease patient E (a woman in her 60s), the RBANS neuropsychological test was administered before taking CareAge and 3 months and 10 days after taking it, and the results are shown in comparison in Figures 13 and 14.

[0065] Figures 5 to 14 suggest that while CareAge's effect on improving Alzheimer's disease is insufficient, it does show a cognitive improvement effect in individuals with mild cognitive impairment.

Claims

1. A medicine for preventing and improving memory loss, characterized by containing red ginseng, Polygala tenuifolia, Angelica sinensis, Ligusticum chuanxiong, Peony root, Rehmannia glutinosa, Licorice root, Poria cocos, Atractylodes macrocephala, Viper rhizome, Dioscorea japonica, Schisandra chinensis, and ox bile as active ingredients.

2. The forgetfulness prevention and improvement drug according to Claim 1, containing as active ingredients: Angelica sinensis 10 to 1,000 parts by weight, Ligusticum chuanxiong 10 to 2,500 parts by weight, Peony root 10 to 2,500 parts by weight, Rehmannia glutinosa 10 to 2,000 parts by weight, Red ginseng 1,400 to 10,000 parts by weight, Licorice root 40 to 1,000 parts by weight, Poria cocos 10 to 30,000 parts by weight, Atractylodes macrocephala 10 to 500 parts by weight, Viper rhizome 150 to 3,000 parts by weight, Dioscorea japonica 60 to 1,000 parts by weight, Schisandra chinensis 150 to 1,500 parts by weight, Ox bile 50 to 500 parts by weight, and Polygala tenuifolia 250 to 500 parts by weight.

Images